Shelley Force Alderd and Nathan Trinklein talk about developing bispecific antibodies for cancer, discussing their journey from academia to entrepreneurship, the mechanism of action of T-cell engagers, challenges in developing therapies for solid tumors, and the importance of strategic company structuring for new drug candidates.